NAD+‑Dependent FOXO1 Silencing Links Inflammaging to Failed Memory T‑Cell Formation

Hypothesis

We're proposing that NAD+ decline acts as a metabolic brake. Chronic inflammation drives CD38‑mediated NAD+ loss, which silences the transcription factor FOXO1 by preventing its SIRT1‑dependent deacetylation. Acetylated FOXO1 is excluded from the nucleus, leading to reduced expression of memory‑associated genes (Tcf7, Il7r, Bcl2) and a block in the formation of long‑lived memory T cells. This creates a metabolically enforced checkpoint, it's limiting clonal expansion during acute inflammation but, when inflammation persists, results in premature T‑cell exhaustion and weakened vaccine responses.

Mechanistic reasoning

1. CD38 as NAD+ sink – Inflammasome activation (NF‑κB/NLRP3) up‑regulates CD38 on macrophages and T cells, consuming NAD+ and generating cADPR‑triggered Ca2+ flux that sustains NLRP3 activity [Chronic inflammation causes a reduction in NAD+] [NAD depletion primes cells for inflammatory behavior] [PubMed 32407845].

2. NAD+ controls FOXO1 via SIRT1 – SIRT1 deacetylates FOXO1 in an NAD+-dependent manner; low NAD+ reduces SIRT1 activity, leaving FOXO1 hyper‑acetylated and cytoplasmic [Cell Metabolism 2016].

3. FOXO1 governs memory programming – Nuclear FOXO1 directly activates Tcf7 and Il7r, promoting stem‑like memory phenotypes and survival [Immunity 2011].

4. Outcome – In inflamed aged tissues, CD38‑driven NAD+ depletion keeps FOXO1 acetylated, silencing memory genes, forcing T cells into a glycolytic, short‑lived effector state that progresses to exhaustion [Frontiers in Aging 2025].

Testable predictions

• Prediction 1: In aged mice with chronic low‑grade inflammation (e.g., LPS‑induced peritoneal inflammation), pharmacological NAD+ precursors (NR or NMN) will increase nuclear FOXO1 deacetylation, boost Tcf7/Il7r expression, and enhance the frequency of vaccine‑induced memory CD8+ T cells compared with vehicle.

• Prediction 2: Genetic mimic of FOXO1 acetylation (FOXO1‑3KQ) will abolish the memory‑enhancing effect of NAD+ supplementation, despite restored NAD+ levels.

• Prediction 3: CD38 knockout or inhibition (using 78c) will raise NAD+ levels, increase SIRT1 activity, and rescue FOXO1 nuclear localisation even in the presence of SASP‑rich senescent cell supernatants.

Falsifiable outcomes

• If NAD+ supplementation doesn't increase nuclear FOXO1 or memory T‑cell frequencies in inflamed aged mice, the hypothesis is weakened.

• If FOXO1‑3KQ mice still show improved memory formation after NAD+ boosting, the FOXO1‑centric mechanism is not essential.

• If CD38 inhibition does not raise nuclear FOXO1 despite NAD+ rise, alternative NAD+‑dependent pathways must be considered.

Experimental outline

1. Models – 20‑month‑old C57BL/6 mice; chronic LPS low‑dose osmotic pump to mimic inflammaging; OT‑I TCR transgenic for OVA‑specific response.
2. Interventions – NR (400 mg/kg/day) vs vehicle; CD38 inhibitor 78c (10 mg/kg i.p. BID); FOXO1‑3KQ knock‑in mice.
3. Readouts – NAD+ levels (LC‑MS); SIRT1 activity assay; FOXO1 acetylation (immunoprecipitation + Western); nuclear FOXO1 (imaging flow cytometry); Tcf7/Il7r mRNA (qPCR); antigen‑specific CD8+ T‑cell tetramer staining; effector vs memory phenotype (CD62L, CD44, KLRG1, CD127); secondary challenge assay (vaccinia‑OVA) to gauge recall expansion.
4. Controls – Young (3‑month) mice; senescent cell‑free supernatants.

If the data match predictions, the hypothesis would position NAD+ decline not merely as a metabolic side‑effect but as an active immunological checkpoint that links inflammaging to failed adaptive memory, it's offering a precise target (CD38‑FOXO1‑SIRT1 axis) for rejuvenating vaccine efficacy in the elderly.